Introduction
Recent epidemiological data show that ovarian cancer accounts for *30% of all newly diagnosed gynecologic cancers and 53% of gynecologic cancer deaths (Greenlee et al., 2001; Daly and Obrams, 1998; Landis et al., 1998; Hoskins, 1995) . The high rate of mortality associated with ovarian cancer is a consequence of the fact that these tumors are usually diagnosed as very late stage tumors which have frequently already spread beyond the ovary. Clearly, an eective late stage therapy is needed.
Retinoids are a group of natural derivatives and synthetic analogs of vitamin A that are required for essential life processes. Although their precise mechanism of action has yet to be fully elucidated, it is known that retinoids function by interacting with a family of nuclear receptors. These receptors are the so-called retinoic acid receptors or RARs and the retinoid-Xreceptors or RXRs (for review see Mangelsdorf et al., 1994) . Many laboratories including our own have shown that retinoids inhibit the growth of a wide variety of tumor cells including ovarian carcinoma cells both in vivo and in vitro (Caliaro et al., 1994; Chao et al., 1997; Grunt et al., 1991 Grunt et al., , 1992a  for review see Zhang et al., 2000) . Previous studies from our laboratory have investigated the eect of all-transretinoic acid (RA) on the growth of ovarian carcinoma cells (Wu et al., 1997a) . The growth of the cell line CA-OV3 was found to be inhibited by RA treatment while the growth of SK-OV3 cells was not. Moreover, we determined that RA treatment blocked cell cycle progression in G-0 and/or G-1. In addition, we have demonstrated that ovarian carcinoma cells can be converted from RA sensitive to RA resistant and vice versa by modulation of the levels and/or function of the RARs and RXRs (Wu et al., 1997b (Wu et al., , 1998a Soprano et al., 1996) .
In this study we set out to identify potential cell cycle gene targets which mediate retinoid dependent growth suppression of ovarian carcinoma cells. Since retinoid inhibited cells are blocked in G-0 and/or G-1 we compared the expression and activity of cell cycle genes known to function in the RB pathway in RA sensitive CA-OV3 cells and RA resistant SK-OV3 cells. Our most striking ®ndings were that retinoid treatment of CA-OV3 cells exhibited signi®cant decreases in hyperphosphorylated RB and RB-2/p130 and corresponding signi®cant increases in the levels of hypophosphorylated and/or partially phosphorylated RB-2/ p130 and hypophosphorylated RB. Also, evidence is presented that suggests that RA alters the activity of G-1 kinases such as cdk 2, cdk 4 and cdk 6 potentially by inducing the cdk inhibitor p27. As a result, RB and RB-2/p130 phosphorylation is inhibited and cell cycle progression arrests in G-0/G-1. These results suggest that components of the pocket protein pathways represent important targets which mediate ovarian carcinoma cell growth suppression by RA.
Results
Effect of RA on steady state mRNA levels of cell cycle genes in CA-OV3 and SK-OV3 cells Previous work from our laboratory has shown that the ovarian carcinoma cell line CA-OV3 is sensitive to RA treatment while the SK-OV3 cell line is resistant (Wu et al., 1997a) . In an attempt to identify potential growth regulatory targets of RA we initially compared changes in expression of a representative group of cell cycle genes in CA-OV3 and SK-OV3 cells with and without RA treatment. Cells were treated with 10 76 M RA or an equivalent amount of ethanol for 1, 2 or 3 days. RNA was isolated and analysed by RNAse protection analysis using riboprobes of cell cycle genes prepared from various multiprobe template sets obtained from Pharmingen. Figure 1a shows RNAse protection analysis of the steady state levels of RB-2/p130, RB, p107, p53, p27, p21, p18, p16 and the housekeeping gene, GAPDH. We found that expression of p53, p21 and p16 was extremely low in both control and RA treated SK-OV3 cells in comparison to similarly treated CA-OV3 cells. RB-2/p130, RB, p107 and p16 were slightly induced (twofold or less) by RA treatment in CA-OV3 cells but not in SK-OV3 cells. Figure 1b shows that the steady state mRNA level of cdk 1, cdk 2, and cdk 4 mRNA was very similar in CA-OV3 and SK-OV3 cells and did not change with RA treatment. This was also true of the E2F family as well as their transcription partners, DP-1 and DP-2 (Figure 1c ).
Effect of RA on expression of RB family proteins
Many cell cycle genes exhibit post-transcriptional regulation. Therefore, we next examined the protein level of several representative cell cycle genes using Western blot analysis. Since RA has been previously shown to induce a mid to late G-1 block in cell cycle progression we initially focused on analysis of the RB family of proteins which are well known to regulate progression through the G-1 stage of the cell cycle. CA-OV3 and SK-OV3 cells treated with either 10 76 M RA or ethanol were harvested at day 0, 3 and 5 after treatment and whole cell protein extracts prepared. It should be noted that our previous results had shown the most dramatic eect of RA on cell growth occurred between 3 and 5 days of treatment (Wu et al., 1997a (Wu et al., ,b, 1998a . As can be seen in Figure 2a , Western blot analysis of RB protein showed a dramatic change in RA treated CA-OV3 cells. RB protein appears as a series of closely migrating bands in control treated CA-OV3 cells and cells treated with RA for only 1 day. These multiple bands most likely represent various phosphorylated forms of RB. However, by 3 days of RA treatment (when growth inhibition and cell cycle arrest can begin to be observed), the multiple forms of RB appear to be converted to a single, intense, faster migrating band which most likely represents unphosphorylated RB. This change was more prominent by 5 days of treatment, when maximum growth inhibition occurs. This change in phosphorylation status following RA treatment is related to growth suppression since a similar change is not observed in RA resistant SK-OV3 cells treated with RA (Figure 2b) . A broad intense band corresponding to phosphorylated RB was observed in both control and RA treated SK-OV3 cells on day 0, 1 and 3 after treatment. On day 5, both control and RA treated SK-OV3 cells exhibit a sharper, faster migrating band corresponding to unphosphorylated RB. However, since this was observed in both control and RA treated cells it most likely represents reduction in growth due to cell crowding and is not an eect speci®c to RA treatment.
The expression of RB-2/p130 in RA treated CA-OV3 cells is shown in the middle panel of Figure 2a . RB2/ p130 was barely detectable in actively proliferating CA-OV3 cells. However, in CA-OV3 cells treated with RA, a dramatic increase in RB-2/p130 expression was observed. It should be noted that this increase in RB-2/p130 protein levels is most likely related to RA mediated growth arrest since RA resistant SK-OV3 cells, although expressing a higher constitutive level of RB-2/p130, do not exhibit an increase upon RA treatment (Figure 2b ). These results suggest that these two members of the RB family of proteins represent speci®c, potentially important gene targets modulated by RA during the process of growth suppression.
Effect of RA on the phosphorylation of RB-2/p130
In light of the signi®cant increase in levels of RB-2/ p130 in CA-OV3 cells growth arrested by RA, we further investigated the nature of the RB-2/p130 which accumulated upon RA treatment. RB-2/p130 has been shown to migrate as three distinct bands, representing its hypophosphorylated form (form 1), a partially phosphorylated form (form 2) and the hyperphosphorylated form (form 3) (Mayol and Grana, 1997) . RB-2/p130 form 1 and 2 are characteristic of growth arrested cells and most likely mediate growth suppression by binding and inhibiting the activity of members of the E2F family of transcription factors. In order to better resolve the three forms of RB-2/p130, we altered the percentage of polyacrylamide and the gel running time. As can be seen in Figure 3 , we found that RA treatment of CA-OV3 cells caused both a decrease of RB-2/p130 form 3 and the appearance of a faster migrating RB-2/p130 form 2 (lanes 2 and 5). This suggested that RA treatment resulted in a partial dephosphorylation of RB-2/p130. Fully de-phosphorylated RB-2/p130 (form 1) is observable in lanes 3 and 6 and was generated by treating control lysates with lambda phosphatase, a non-speci®c serine/threonine and tyrosine phosphatase. The distinct forms are not as clear in the samples prepared from CA-OV3 cells treated with RA for 5 days. This is due to the large increase in RB-2/p130 protein described previously. Nevertheless, it is clear that RA treatment caused a visible shift in the migration of the RB-2/p130 protein to a position located between forms 1 and 3. This species is most likely RB-2/p130 form 2. (b) and (c) represent three dierent sets of templates (hcc2, hcc1 and hTS1, PharMingen) used to synthesize antisense probes for RNase protection assay. GAPDH is included in each set of templates to control for the amount of RNA used in each reaction. All the comparisons were made using NIH image program Effect of RA on cyclin and cdk protein levels
In order to begin to understand the mechanism of RA mediated RB hypophosphorylation we analysed the expression of various cyclins, cdks and cdk inhibitory proteins since these proteins are known to regulate RB phosphorylation (Sidle et al., 1996) . During mid G-1, D type cyclins form complexes with cdk 4 or cdk 6 and these activated kinases phosphorylate RB Mittnacht, 1998) . This kinase activity is itself speci®cally regulated by the Ink and Kip family of proteins (Slingerland and Pagano, 2000) . Figure 4a shows that in CA-OV3 cells, cyclin D1 protein level decreases with RA treatment. This eect could ®rst be observed on day 3 and became more prominent on day 5. That this pattern is speci®c for cyclin D1 is shown by the fact that expression of cyclins A,B or E do not change upon RA treatment. In contrast, SK-OV3 cells do not exhibit a change in expression of cyclins A,B,D1 or E following RA treatment ( Figure 4b ). Figure 4c , d show that the protein level of cdk 2, cdk 4 and cdk 6 did not signi®cantly change in response to RA treatment in either the CA-OV3 or SK-OV3 cell line.
Effect of RA on cdk 2, cdk 4 and cdk 6 kinase activity
Our previously described studies suggested that RA dependent inhibition of RB phosphorylation in CA-OV3 cells might result at least in part from a reduction in cyclin D1 expression but not from changes in cdk 2,4 or 6 protein levels. However, it was possible that RA could alter the kinase activity of these cdks. In order to investigate this, we performed cdk-speci®c in vitro kinase assays in RA sensitive CA-OV3 cells. CA-OV3 cells were treated with 10 76 M RA. Cell extracts were prepared on day 1, 3 and 5 after treatment and assayed using Histone H1 as a substrate for cdk 2 and GST-RB for cdk 4 and cdk 6. Figure 5 shows the results of these kinase assays. Cdk 2 kinase activity was signi®cantly reduced in RA treated CA-OV3 cells on day 3 and day 5 following treatment. Cdk 4 and cdk 6 kinase activity levels were only slightly reduced. Nevertheless, the timing of the reduction in cdk activity corresponds closely with the time when RB dephosphorylation is observed. This suggests that RB dephosphorylation may occur as a result of RA reduction in cdk kinase activity.
Effect of RA on cdk inhibitory protein expression
Activity of the cdk proteins has been shown to be regulated by members of the Ink and Kip family of proteins (also referred to as the cdk inhibitory proteins). This gene family includes p15, p16, p18, p19, p21, p27 and p57. We found that at least under the conditions we used for Western blot analysis, p27 could be detected in both ovarian carcinoma cell lines, p16 could be detected only in CA-OV3 cells while p15 and p21 could be detected in neither. Figure 6 shows that in CA-OV3 cells there is an increase in p27 protein level on day 3 and day 5 when control and RA treated cells are compared. No comparable response was observed in SK-OV3 cells. In contrast to the changes observed in p27, there is no signi®cant change in the p16 protein level in CA-OV3 cells. The increase in p27 protein levels in RA treated CA-OV3 cells is consistent with the decrease in cdk activity and RB phosphorylation described previously.
Effect of RA on the association between p27 and cyclin E and RB-2/p130 and E2F4
Since we observed a signi®cant increase in the expression of p27 following RA treatment of CA- Figure 1 . The cells were harvested 3 and 5 days after either ethanol (C3 or C5) or retinoid (RA3 or RA5) treatment. Total protein was prepared as described in Materials and methods. Fifty mg of each protein sample was used for each Western blot assay. To determine the location of hypophosphorylated RB-2/p130, control lysates were treated with lambda phosphatase (l3 or l5). RB-2/p130 forms are indicated with arrows OV3 cells, we next wished to determine if this increase in p27 was associated with a comparable increase in formation of the p27-cyclin E complex. We used a p27 antibody to co-immunoprecipitate p27 and any other proteins associated with it. The immunoprecipitates were analysed by Western blot using antibodies to p27 and cyclin E. Figure 7a shows that p27 protein level increased with RA treatment, which is also consistent with the previous Western blot results. When the same membrane was blotted with cyclin E antibody, we found that the amount of cyclin E protein bound to p27 also increased with RA treatment. Likewise, the immunoprecipitation assay presented in Figure 7b shows the previously observed increase in RB-2/p130 protein level after 3 or 5 days of RA treatment and a comparable increase in the amount of RB-2/p130 associated with E2F4. In light of our previous results on analysis of phosphorylated forms of RB-2/p130, shown in Figure 3 , it is likely that the majority of RB-2/p130 co-precipitating with E2F4 is form 1 and 2.
These results are consistent with the possibility that RA treatment causes a decrease in cdk 2 activity by increasing the amount of the cdk inhibitor p27. This increase in p27 likely causes a reduction in the activity of the cyclin E/cdk 2 complex by virtue of its increased association with cyclin E. As a result, RB-2/p130 is either not phosphorylated or only partially phosphorylated and thus remains associated with E2F4. 
Discussion
We set out to elucidate the molecular mechanism by which retinoids inhibit the growth of ovarian carcinoma cells. Our focus was on the eects of retinoid treatment on cell cycle gene expression in ovarian carcinoma cell lines. We can draw several major conclusions from these initial studies: (1) The most unique ®nding from our study is that CA-OV3 cells exhibited a very signi®cant increase in RB-2/p130 levels. More speci®-cally, we observed a decrease in hyperphosphorylated RB-2/p130 (form 3) and a corresponding signi®cant increase in hypophosphorylated and/or partially phosphorylated RB-2/p130 protein (form 1 and 2). (2) Our Western blot assay results showed that retinoidsensitive CA-OV3 cells exhibited signi®cant hypophosphorylation of RB protein upon RA treatment; (3) RA treatment reduced the activity of G-1 kinases such as cdk 2, cdk 4 and cdk 6; and (4) RA treatment of CA-OV3 cells increased the level of p27 and its association with cyclin E. These results suggest that suppression of ovarian carcinoma cell growth by retinoids is mediated by the accumulation of hypophosphorylated and partially phosphorylated RB-2/p130 (forms 1 and 2) which remains associated with E2F4.
As stated above, the most unique ®nding from our study is that retinoid treatment of CA-OV3 cells leads to a very signi®cant decrease in hyperphosphorylated RB-2/p130 (form 3) and a corresponding signi®cant increase in the accumulation of unphosphorylated and/ or partially phosphorylated RB-2/p130 (forms 1 and 2). RB-2/p130 is the newest member of the retinoblastoma protein family (Mayol et al., 1993; Li et al., 1993; Hannon et al., 1993) . It has been found that RB-2/p130 complexes with E2F4 in G-0 and early G-1. G-1 cyclin/cdk complexes phosphorylate RB-2/p130 leading to dissociation of the RB-2/E2F4 complex and cell cycle progression (for review see Paggi et al., 1996; Mayol et al., 1996; Mayol and Grana, 1997; Nevins, 1998) . To date, there has been no report on RB-2/p130 expression in normal and tumorigenic ovarian tissues. Moreover, there is very limited knowledge about the eect of RA on RB-2/p130 expression and phosphorylation. Within the past few years, there are only a few reports which describe changes of RB-2/p130 protein level after RA treatment (Hsu et al., 1997; Li et al., 1998; Zancai et al., 1998; Baldassarre et al., 2000) . Two studies described an increase in RB-2/p130 in NT2/D1 embryonal carcinoma cells and B-lymphoblastoid cell lines respectively after RA treatment (Baldassarre et Figure 5 Kinase assays to determine Cdk 2, Cdk 4 and Cdk 6 kinase activity after RA treatment of CA-OV3 cells. CA-OV3 cells were treated as described in Figure 1 . The cells were harvested at day 1, 3 and 5 after RA or ethanol treatment and assayed for cdk 2, cdk 4 and cdk 6 kinase activity. Two hundred mg of protein from each sample was used for immunoprecipitation with antibodies to cdk 2, 4, and 6 (labeled on the right side of each panel). The precipitant was incubated with corresponding kinase buer and substrate (Histone H1 for cdk 2 and GST-RB for cdk 4 and 6) to allow phosphorylation of the substrate. The reactions were then loaded on 10% SDS ± PAGE gels and processed for autoradiography Figure 6 Western blot assay to determine Cdk inhibitory protein levels after RA treatment of CA-OV3 and SK-OV3 cells. CA-OV3 and SK-OV3 cells were treated as described in Figure 1 . Cells were harvested on day 1, 3 and 5 after ethanol (C) or retinoid (RA) treatment. Fifty micrograms of protein samples, prepared as described in Materials and methods, were loaded on 15% SDS ± PAGE gels and assayed by Western blotting using antibodies to p27 and p16. Zancai et al., 1998) . However, neither study determined the phosphorylation status of the RB-2/ p130. Another study reported that RA increased the level of nuclear E2F4, p107 and RB-2/p130 in normal human bronchial epithelial (HBE) cells (Li et al., 1998) . Also, Hsu et al. (1997) found that in human hepatoma Hep3B cells, RA treatment caused RB-2/p130 hyperphosphorylation, p34(cdc2) activation and RA induced cell death. In our study, RA caused signi®cant decrease in hyperphosphorylated RB-2/p130 (form 3) and a corresponding increase in the level of unphosphorylated and/or partially phosphorylated RB-2/p130 (form 1 and 2) in CA-OV3 cells but not in RA resistant SK-OV3 cells. The decrease in hyperphosphorylated RB-2/ p130 and the increase of unphosphorylated and/or partially phosphorylated RB-2/p130 became apparent after 3 days of RA treatment, corresponding to when growth inhibition became apparent. The correspondence between growth inhibition and hypophosphorylated and/or partially phosphorylated RB-2/p130 accumulation suggests that RB-2/p130 might be a mediator of RA induced growth inhibition. However, a number of questions remain to be answered. For example, RA treated CA-OV3 cells exhibited both RB hypophosphorylation and unphosphorylated and/or partially phosphorylated RB-2/p130 accumulation. Is this simply redundancy or are these two members of the retinoblastoma family controlling the expression and/or function of dierent sets of target genes? It is likely that both RB and RB-2/p130 are needed to fully inhibit cell cycle progression in light of recent studies by Sage et al. (2000) and Dannenberg et al. (2000) . These reports show that in order for cells to exhibit complete independence from cell cycle regulation, it is necessary for all three members of the RB gene family to be knocked-out.
In control treated, actively growing CA-OV3 cells, RB migrated in a microheterogeneous pattern on SDS ± PAGE, suggesting various degrees of phosphorylation. However, in response to RA treatment, RB became hypophosphorylated and migrated as a single, fast-moving band on SDS ± PAGE. This pattern became apparent by day 3, which corresponded to the start of growth inhibition. These results are consistent with other reports which show that RA causes hypophosphorylation of RB in various cell lines (Matsuo and Thiele, 1998; Naderi and Blomho, 1999; Seewaldt et al., 1999; Spinella et al., 1999; Sueoka et al., 1999; Teixeira and Pratt, 1997; Watanabe et al., 1999; Wilcken et al., 1996; Zancai et al., 1998) . For example, Wilcken et al. (1996) reported hypophosphorylation of RB in T-47D breast cancer cells upon RA treatment. Matsuo and Thiele (1998) reported a complete down-regulation of G-1 cyclin/cdk activity and hypophosphorylated RB protein in SMS-KCNR human neuroblastoma cells. Spinella et al. (1999) found that in the human embryonic carcinoma cell line NT2/D1, RA caused a progressive decline in cyclin D1 and hypophosphorylation of RB. Finally, Naderi and Blomho (1999) found that RA prevented phosphorylation of RB in normal human B lymphocytes when these cells were stimulated with anti-m and SAC. These ®ndings suggest that hypophosphorylation of RB is a common mechanism mediating inhibition of cell cycle progression upon RA treatment.
The functions of all three members of the RB family are regulated by cell cycle-dependent phosphorylation (Baldi et al., 1995; Buchkovich et al., 1989; Chen et al., 1989; Claudio et al., 1996; DeCaprio et al., 1989; Giordano et al., 1991; Mihara et al., 1989; Mayol et al., 1995) . Since we have observed signi®cant changes in the phosphorylation status of RB and RB-2/p130, it was logical to examine the level and activity of various cyclins, cdks and cdk inhibitory proteins. In CA-OV3 cells cyclin D1 seems to be the only cyclin that has a signi®cant change in level upon RA treatment. The protein levels of cdk 2, 4 and 6 did not seem to change in response to RA treatment. However, the level of p27 protein increased signi®cantly after 3 days of RA treatment. None of these changes were observed in the RA resistant SK-OV3 cells. When we examined the kinase activity of cdk 2, 4 and 6 in CA-OV3 cells, we noticed a down-regulation of cdk 2 kinase activity after Figure 7 Analysis of the eect of RA treatment on the association of p27 and cyclin E and RB-2/p130 and E2F4. (a) Immunoprecipitation assays were performed to determine if RA treatment altered the amount of p27 associating with cyclin E. CA-OV3 cells were treated with 10 76 M RA or ethanol for 3 or 5 days. Total cell extract was prepared as described in Materials and methods. Three hundred mg of total cell extract was used to incubate with 2 mg of antibodies to p27. The proteins were resolved on SDS ± PAGE and blotted with either cyclin E or p27 as indicated. (Top): protein extract was immunoprecipitated with p27 antibody, then blotted with p27 antibody. (Bottom): protein extract was immunoprecipitated with p27, then blotted with cyclin E antibody. (b) In order to determine if RA treatment altered the amount of RB-2/p130 associating with E2F4, CA-OV3 cells were treated as described in a. Cell extracts were immunoprecipitated with antibodies to either RB-2/p130 or E2F4. Non-immune IgG was used as a negative control. SDS ± PAGE resolved immunoprecipitates were blotted with RB-2/p130 antibody. C, control samples; R, RA treated samples. Duration of treatment is indicated after C or R 3 days of RA treatment, corresponding to the p27 level increase. Although the kinase activity of cdk 4 and 6 also decreased, it did not seem to change as signi®cantly as cdk 2. Moreover, co-immunoprecipitation studies showed that RA treatment resulted in an increase in the association of p27 with cyclin E. Based on these results, it is reasonable to hypothesize that p27 inhibits cdk 2 kinase activity leading to RB and RB-2/p130 hypophosphorylation in G-1. It has been shown in other model systems that the cyclin D/cdk 4 and cdk 6 complexes appear to be responsible for early G-1 phosphorylation of RB, while the cyclin E/cdk 2 complex is responsible for mid to late G-1 phosphorylation of RB (Mittnacht, 1998; Paggi et al., 1996) . Since cdk 2 is the partner for cyclin E, it is likely that the RA-dependent increase in p27 results in increased binding of the cyclin E/cdk 2 complex by p27, leading to decreased cyclin E/cdk 2 kinase activity and, as a consequence, hypophosphorylation of RB in mid to late G-1. This idea is supported by studies which suggest that p27 up-regulation could be a primary response in RA treated cells (Borriello et al., 2000; Matsuo and Thiele, 1998; Weber et al., 1999; Zancai et al., 1998; Zhu et al., 1997) . Interestingly this upregulation is at the protein level but not at the mRNA level (Borriello et al., 2000; Matsuo and Thiele, 1998; Zancai et al., 1998) . Borriello et al. (2000) showed that the accumulation of p27 is due to increased proteasome-dependent degradation. In contrast, another report utilizing the human small cell lung carcinoma cell line H209 which is RAR-b negative and resistant to RA induced growth inhibition, showed no change of p27 expression upon RA treatment. However, when this cell line was transfected with RAR-b, the cells showed growth inhibition and p27 up-regulation (Weber et al., 1999) . This suggests that RA induced growth arrest of human small cell lung carcinoma cells involves RAR-b mediated induction of p27. Our ®nding that RA treatment leads to an increase in p27 protein level and decrease in cdk 2 activity is consistent with those other reports which indicate that p27 up regulation is controlled post-translationally. The results from our RNAse protection assays did not support direct induction of transcription of p27. It will be interesting to look at p27 protein stability in response to RA treatment in our system. Clearly, dierent cell models utilize dierent mechanisms to achieve the same goal in response to retinoid treatment: altered phosphorylation of the retinoblastoma protein family leading to G-1 arrest.
Materials and methods

Cell lines and culture conditions
CA-OV3 and SK-OV3 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). All stock cultures were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum, 2 mM Lglutamine, 100 units/ml penicillin and streptomycin. The SK-OV3 cells were routinely split at a ratio of 1:10 weekly and the CA-OV3 cells were split at 1:8 ratio weekly. Plates were placed in a 98% humidi®ed, 5% CO 2 incubator.
Retinoids
All-trans-RA was kindly supplied by Homann-La Roche at Nutley, New Jersey. Retinoid stock solutions (10 73 M) in ethanol were prepared fresh every 2 weeks. All procedures involving retinoids were carried out under subdued light. In each experiment, control cultures were treated with an equivalent amount of ethanol.
RNA isolation
Ovarian cancer cells were treated with either ethanol or alltrans-RA at a concentration of 10 76 M for 1, 2 and 3 days. Total cellular RNA was then extracted using RNAzol B (TelTest, Inc., Friendswood, TX, USA) according to the manufacturer's instructions as described previously. RNA was quantitated by absorbence at 260 nm and purity assessed by absorbence at 280 nm. The integrity of RNA samples was checked by loading 2 mg of RNA on a formaldehyde denaturing agarose gel and staining with ethidium bromide as we have described previously (Wu et al., 1997a (Wu et al., ,b, 1998a .
RNase protection analysis
The RNase protection assay was used to determine the steady-state mRNA level of the cell cycle genes we studied. The multi-probe sets hcc-1, hcc-2 and hTS-1 were purchased from PharMingen (San Diego, CA, USA) and the procedure recommended by the manufacturer followed. Hcc-1 (human cell cycle-1) contained cdk 1, cdk 2, cdk 3, cdk 4, p27, p21, PISSLRE and p16. Hcc-2 included RB2/p130, RB, p107, p53, P57, p27, p21, p19, p18, p16 and p14/15. HTS-1 (human tumor suppressor-1) contained RB-2/p130, RB, p107, DP1, DP2, E2F1, E2F2 and E2F4. Two housekeeping genes, L32 and GAPD, were included in each set to allow assessment of total RNA levels of normalization. All the template sets contain DNA templates which can be used for T7 polymerase-directed synthesis of 32 P-labeled, anti-sense RNA probes that can hybridize with target human mRNA encoding the above genes. The excess free probe and other single-stranded RNA molecules were then digested with RNase. The hybridized RNA probe was protected from the RNase and resolved on denaturing polyacrylamide gels and imaged by autoradiography. The identity and quantity of each mRNA species in the original RNA sample was then determined based on the size of the bands and the signal intensities. The density of the bands were analysed using the NIH Image program. Comparison of the level of mRNA was made after normalization to GAPDH.
The RNA samples used in these assays were prepared using RNAzol TM B method as described above. Ten mg of total RNA for each sample was used to determine the expression of the genes.
Total protein isolation and Western blot analysis
To determine the expression of various cell cycle proteins following RA treatment, CA-OV3 and SK-OV3 cells were treated for various lengths of time with either RA or ethanol and then harvested by scraping. The cell pellets were resuspended in lysis buer supplemented with protease inhibitors (50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 200 uM Na 3 VO 4 , 10 mM sodium pyrophosphate, 100 mM NaF, 1% Triton X-100, 30 mM pnitrophenyl phosphate) (Sigma). Protease inhibitors added before use were: 10 mg/ml leupeptin, 1 mg/ml pepstatin, 10 mg/ml trypsin inhibitor, 70 mg/ml TPCK, 1 mM PMSF). About 1 ml lysis buer was added for every 10 7 cell and incubated on ice for 15 min. Then the cell lysate was passed through 22G syringe repeatedly and centrifuged at 4000 for 15 min at 48C. The supernatant was saved. Usually, 50 mg of protein was analysed by separation on 10% SDS ± PAGE gels. Electrophoresis was carried out at 100 V/30mA for 4*6 h. In order to separate RB-2/p130 forms 1,2 and 3, gels were run 80 V/20mA for *8 ± 10 h. Separated proteins were transferred to PVDF membrane by electroblotting using the Hoeer Transfor Apparatus.
Antibody detection of specific proteins
The ®lters were blocked by incubating overnight at 48C, or 1 h at room temperature in 5% non-fat dry milk in TBST (20 mM Tris, pH 7.6, 150 mM sodium chloride and 0.05% Tween-20). The blocking reagent was then removed and the primary antibodies were diluted in 10 ml blocking reagent (TBST plus 5% non-fat dry milk) and incubated with the ®lters in a small plastic container at room temperature for 1 h on a rocking platform.
The primary antibodies we used are as follows: RB (C-15), p107 (C18), cyclin D1 (HD11), cyclin E (HE12), cdk 2 (M2), cdk 4 (C-22), cdk 6 (C-21), p27 (F-8), p21 (187), p16 (C-20) from Santa Cruz Biotechnology. The RB-2/p130, E2F4, cyclin A and cyclin B antibodies were prepared by Dr Antonio Giordano at Thomas Jeerson University (Baldi et al., 1995) .
The blots were brie¯y rinsed in TBST, washed once for 15 min and three times for 5 min using large volumes of TBST with gentle rocking. After washing the blots were incubated with secondary antibody at room temperature for 1 h. The secondary antibody used was anti-mouse or antirabbit IgG conjugated to horseradish peroxidase (Amersham Life Sciences). The secondary antibody was diluted in 15 ml of TBST plus 5% non-fat dry milk (anti-rabbit was used at 1 : 2000 dilution, anti-mouse was used at 1 : 5000 dilution). After removal of the secondary antibody, blots were again washed and the protein bands visualized using Enhanced Chemiluminescence (ECL) (Amersham).
Cdk 4, cdk 6, and cdk 2 kinase assays In order to assay for cdk 4 and cdk 6 kinase activity, cells were rinsed twice with ice cold PBS and then scraped into 50 ml Falcon tubes and spun at 2000 r.p.m. for 10 min at 48C to collect the cell pellets. The cells were lysed in lysis buer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 0.1% Tween-20 and 10% glycerol with 1 mM DTT, 0.1 mM PMSF, 5 mg/ml pepstatin, 1 mM NaF, 10 mg/ml aprotinin, 10 mM b-glycerophosphate and 0.1 mM Na 3 VO 4 added before use. The cell lysates were kept on ice for 15 min and passed through a 22G syringe needle repeatedly. Then the lysates were centrifuged at 4000 for 15 min at 48C, and the supernatant was saved.
All the antibodies were preincubated with protein G plus/ protein A agarose beads (Calbiochem) for 1 h at 48C before use. Two hundred mg of each cell lysate was precleared with 1 mg normal rabbit IgG (CalBiochem) and incubated with 1 mg antibody to cdk 4 or cdk 6 (Santa Cruz) for 3 h to overnight at 48C.
The beads were washed twice with above mentioned lysis buer (protease inhibitors are optional) and four times with RB kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 and 1 mM DTT). The beads were then incubated with 25 ml of RB kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 10 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 , 1 mM NaF, 20 mM ATP, 10 mCi [g-32 P]ATP and 1 mg GST-RB (Santa Cruz) at 308C for 30 min.
The kinase reaction was stopped by adding ®ve times the volume of elution buer (10 mM Tris, pH 7.6, 1% SDS, 1 mM Na 3 VO 4 and 10 mM NaF) followed by boiling for 5 min. The supernatant was saved and then diluted with 10 times volume of dilution buer (1% Triton X-100, 5 mM EDTA, 50 mM NaCl, 10 mM Tris, pH7.6, 10 ug/ml Aprotinin, 10 ug/ml Leupeptin, 10 mM NaF and 1 mM Na 3 VO 4 ) and incubated with 2 mg anti-GST antibody (Santa Cruz) for 2 h to overnight at 48C. Forty ml of protein G plus/protein A agarose beads were then added and incubated for 1 h to precipitate the antigen-antibody complex. The beads were resuspended in Laemmli sample buer and boiled for 5 min. Ten per cent SDS ± PAGE was used to resolve the samples. The gel was dried and exposed to X-ray ®lm.
The cdk 2 assay was based on the method described by Zhou et al. (1997) . The cells were lysed using cdk 2 lysis buer containing 16PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 600 mM PMSF, 60 mg/ml aprotinin, 1 mM sodium orthovanadate. Two hundred mg of each cell lysate was precleared with 1 mg normal rabbit IgG and incubated with 1 mg antibody to cdk 2 (Santa Cruz) for 3 h to overnight at 48C. All the antibodies were preincubated with protein G plus/protein A agarose beads for 1 h at 48C. The beads were washed twice with RIPA buer (16PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) and four times with Histone kinase buer (50 mM Tris, pH 7.4, 10 mM MgCl 2 and 1 mM DTT). The beads were then incubated with 25 ml of Histone kinase buer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 1 mM DTT, 20 mM ATP, 2 mM EGTA, 10 mCi[g-32 P]ATP and 5 mg Histone H1 (Sigma)) at 308C for 30 min. Kinase reaction was stopped by Laemmli buer and loaded on 10% SDS ± PAGE after boiling for 5 min. The gel was processed as described above.
